Q1 2023 Corteva Inc Earnings Call
Bernie and shows just how far we've come.
Today, we're also updating our previously announced guidance for the full year net sales are now expected to grow 7% and operating EBITDA, 13% at the midpoint over prior year.
Operating EPS is expected to be in the range of $2 80 to $3.
Strategically we continue to make choices to strengthen our portfolio mix and accelerate growth and margin expansion.
As a reminder, we expect the U S soybean market penetration percentage for analyst to be in the mid fifties this year.
<unk>, our growing retail brand, which is serving as a catalyst for growth in the medium term, we continue to see robust demand and market acceptance.
30% increase over prior year.
This was led by products I can list and <unk> herbicides, which each grew more than 50% over the same quarter last year.
I'm also pleased with the advancements we've made in all three of our frontier markets in the first quarter.
We see tremendous opportunity in the high growth high value areas of Biofuels specialty oils and proteins as well as biologicals. These.
These growth markets will deliver increased optionality and value to our customers and allow us to work with partners to create new value chains, and cropping systems that will increase both food and fuel security.
In Biofuels, our collaboration with Bungie and Chevron will increase the supply of lower carbon renewable fuels in the U S by using our proprietary winter canola hybrids in a new double cropping system.
We are also collaborating with bungie to develop and commercialize a more nutritious soybean meal for the animal feed industry in the U S aimed at reducing the use of synthetic feed additives.
And biologicals, we successfully acquired Stoller and some Borg in the first quarter.
Which added approximately $19 million of sales in the quarter.
Protection raw material costs were up 7% versus prior year as we sold through higher cost inventory.
The year is obviously off to a great start with first quarter growth led by EMEA and North America, the quarter's performance sets us up well for another year of delivering results.
While we're confident that we're on track to deliver our full year guidance, we expect a greater percentage of revenue and earnings in the second half of the year compared to 2022, largely driven by supply chain improvement and normalization in customer buying behaviors.
We're raising our full year guidance, largely driven by the biologicals acquisitions and operational performance importantly, we remain confident that we're on track to deliver on our 2025 financial targets and with that let me turn it over to Kim.
Thank you Dave on Slide 13, I wanted to briefly share the key topics of our upcoming R&D innovation update as a reminder, the virtual event will be held this coming Tuesday may nine at 930, a M. Eastern it will be a 90 minute webcast, including 30 minutes of Q&A.
And Sam I think Tim our Chief Technology, and digital officer will provide more detail on our leading pipeline and insights into how and where we're choosing to invest in R&D registration details are available on our website and we look forward to your participation at the event.
I'd also like to take a second to highlight that we released our 2020 cases ability and ESG report on April 4th which is available on our website.
Now, let's move onto your questions I would like to remind you that our caution on forward looking statements and non-GAAP measures apply to both our prepared remarks and the following Q&A operator, please provide the Q&A instructions.
Thank you if you would like to signal with questions. Please press star one on your Touchtone telephone. If you are joining us today use a speaker phone. Please make sure mute function is turned off to allow your signal to reach our equipment.
Limit yourself to one question.
That is star one if you would like to signal with question Star one.
And our first question comes from Vincent Andrews with Morgan Stanley .
Thank you and good morning, everyone. Just a question on pricing.
And Europe crop Chem, the pricing was very strong and you referenced sort of pricing for value initiatives. So if you could just give us a little bit more detail on what youre doing there and how different it is and then also if you could just talk a little bit about.
U S seed pricing, which came in at 7% if you could give us some color on on soy seed pricing versus corn seed pricing. Thank you.
Yes, good morning, Vincent So I'll have Robert and Tim answer those questions. Just let me give you a couple of other comments.
Set the stage when it comes to price. So as we mentioned in our prepared remarks, we're seeing very good demand the underlying demand on the farm is still strong and that underpins our.
Our our forward thinking obviously it underpins the guidance that we put out today and we're just seeing a willingness around the world for farmers to maximize yield and productivity. It is really one of the few tools. They have to ensure that theyre going to be a profitable long term. So maybe Robert you want to answer Vincent's question on CP.
Yeah, absolutely thanks, Doug.
Like Chuck is talking about the underlying demand.
It remains unchanged. So when you begin to look at what is price for value and when we talk about that it's the same strategy that we've had across the last year as well, where we say we're looking at our differentiated products, our new products that give a new technology a different technology to the growers that really helps them begin to.
Add value to their to their farm in it it's a it's an opportunity for them to be able to protect yield and an improved yield. So when we talk about <unk>. When we talk about price for value. We're talking about we're going to price in such a way that the farmers are getting to add value and we're getting paid for our technology.
And so it's a strategy we've used over the last year and will continue to use this with price and productivity to help offset the inflation and FX that we've had over the last year and that you've seen it in the first quarter.
Hey, Tim Hey, good morning, Vincent So on North America pricing, obviously off to a strong start in terms of pricing and I'd say, it's turning out consistent with our expectations.
Clearly driven by our strong value proposition.
And in terms of.
Our ability to execute in the field I think we've got several years of.
Of demonstrating that we're going to get paid for value that we deliver in terms of the mix between corn and soy.
I'd say, the first quarter soy numbers, there's some a little bit of an anomaly in that in the sense that we had a route to market change and so.
I think it's showing up at about 1% on soy and the first quarter and thats going to be lower than what we would expect over the course of the season throughout the market change is driven by the move from direct sales in the south and mid south to dealer sales.
And so instead of paying a commission on the backend it's an off invoice discount. So are our gross price is different under the two models, but in the end what are margins. They will it will demonstrate the pricing there.
In terms of how the season's gone I'd say as competitive as normal.
Farmers have been very committed to corn and very strong quarter orders throughout the season and and.
And soybeans are always just a little bit more competitive, but I would say playing out as we expect and I think representative of what we'll see over the course of the season.
And.
And our next question will come from Joel Jackson with BMO.
Hey, good morning, everyone. This is Joseph on for Joel.
So just in terms of free cash flow, which moved up to 36% this quarter.
What would be some of the opportunities to move that above 40% and what work you guys are doing in that area.
Dave why don't you take that question sure, yes, so as we've decided on.
Prepared remarks.
Our release were raising the guide for the year, that's really reflects.
Two things one one is the higher EBITDA the higher earnings we also.
Just fine tune it.
Not that significant but it is part of the math.
Fine tuned our capex full year forecast.
In terms of improvements we're here Theres a lot thats going on.
In the organization and in both businesses that it's really giving us.
Greater confidence in terms of our cash flow for the year.
On the other side of the equation, what we have is with some of the timing difference in terms of the distribution between one H two H.
We are obviously going to be carrying a little bit more working capital, including as you would suspect we will have receivables balances that will be weighted down more significantly than our original forecast towards the second half and towards the end of the year. So it's really the balance of those items.
As we look into 'twenty, four and 'twenty five.
We remain very confident in our ability to continue to.
Increased cash flow as well as cash flow conversion and by the way just to tell you a little bit about the conversion numbers that conversion for 2023, the midpoint the $1 3 billion.
Free cash flow represents about 63%.
Our operating earnings so if you will.
Free cash flow divided by our operating earnings forecast. It is implied with our EBIT EBITDA update our EPS update.
Which.
Compared to EBITDA of used EBITDA than is the denominator it would be more in the neighborhood of about 35%. So it also gives you assume some relative measures.
We're very very confident looking forward, we've got the ability to continue to drive towards the kind of numbers that you mentioned in the <unk> and even into the 50% range on cash flow conversion as relates to.
EBITDA as the as the denominator.
And our next question will come from Kevin Mccarthy with vertical research partners.
Good morning.
With regard to crop protection it sounds like Youre seeing good underlying demand would you comment on your current view of channel inventories around the World I think you made a comment in the prepared remarks that buyer patterns were normalizing here and just curious on what you.
Think that.
That could do to the volume experience as the year progresses. Thank you.
Okay, Kevin how are you Rob why don't you take that question.
Yes, Kevin when you began to look at our channel inventory.
We track our distributor distributor inventory as well as our product to ground. So we have a pretty good handle on what's going on in the channel from our inventory standpoint, and when you look at it across across the regions.
Therefore, as they should be at this time of year, especially in North America.
But overall for critical were about normal.
Two hotspots are two exceptions, one is in Asia, where we have <unk>.
<unk> inventory in the channel that is elevated.
But we do believe we're in a better position there than than the.
The industry is from a standpoint of channel inventory there that'll it'll work itself out across the second half of the year and in Latin America Fungicide. Obviously is one that is up as we've talked about.
Q4 in <unk>.
As we got into the drought. So fungicide is something there that also we believe with with normal weather, we will work itself out across the year also.
Again to look at the shift that we've talked about there and how does that impact channel inventory.
Really it's just the shift of first half second half that we're talking about and Thats. The normalization of buying that's happening right now that we're seeing in crop protection.
And this really has a lot of things to do with the supply chain getting better.
Disruptions arent totally gone, but theyre manageable now and so the supply chain have plenty of availability for the farmers so with that.
Don't need to buy right now and then when you began to look at all of the other extraneous factors that are that will impact their decisions from.
Glyphosate pricing dropping in.
I'm looking at how that impacts et cetera.
And quite honestly the retailers are really trying to manage their cash flow and so theyre looking at things as well to make sure that they're empty by the end of the season.
So with all that you would get delayed buying pattern that really is more normal and so when we say normalized you begin to look at prior years before 'twenty, two and you begin to see that.
We're just basically saying that ordering will become more and more like it has been in the past.
And moving on to David Begleiter with Deutsche Bank.
Thank you good morning Chuck.
Chuck commodity prices have been dropping a little bit here at what point is that a concern for you at annual and longer term earnings guidance I know, it's still well above long term rates. So they have dropped a little bit here. Thank you.
Yes, good morning, David.
Look if you step back and you think through the last two years in terms of crop pricing, we've seen very strong crop pricing and one was a record rate.
So that that is where we are coming off of but when you look at 2023, we're still well above mid cycle and crop pricing is still above historical averages. There is still a very tight stocks to use ratio out there and then if you look at the growing market the major growth.
And exporting markets around the world.
Got Argentina that is under a 60 year drought.
It's the worst in 60 years.
You've got the Ukraine still under <unk>.
Significant conflict and not able to produce corn the way they want to.
The drought in southern Brazil looks like it's turned the corner. So we're going to see I think good production out of Brazil, but in our view, it's going to come down to the U S and the planning in the United States and it's too early to talk about that crop right now because it's just going in the ground, but we also believe when we look at the stocks to use models.
That we need two consecutive years that trend yield.
And this may this year may or may not be so look we're still very optimistic about where we are in the cycle now.
You talk about core Teva and the influence of the cycle Oncor Teva that is a bit of a different question. In fact, if you look at the way we frame the value creation opportunity for 2025, $4 $4 billion $20 billion of revenue and 21% to 23% margins a lot of the value creation levers are well within our control.
And of course, we are operating in the AG market, but when you talk about royalty neutrality of that journey. When you talk about the product mix and really.
Optimizing the percentage of differentiated products that we put into the market. When you talk about the number of new products that are going to go into market. In the next couple of years. All of these things I think are well within our control and they are the major knee versus a value creation. So I think there is two points to make today. One is we're very comfortable.
<unk> with where we are in the cycle. In fact, we think that 2023 is going to be a very very good year for agriculture, and then on top of that when you think through our value creation levers a lot of a lot of that will be within our control and it's a matter of execution and as the team has been saying today, we feel very good where we are today in the first quarter is a bit of a test.
Ammonia or that this is a significant amount of new product sales, we put into the market. It was the first time, we hit 25% EBITDA margin in the first quarter. So we like the strategic levers, we're pulling and we think they are adding value.
And our next question will come from Christopher Parkinson with Mizuho.
Great. Thank you so much so when you look at your first quarter EBITDA Bridge I mean, it's clear that you are pricing well above cost.
Positive, but could you just give a little bit further insight on how we should be thinking about that by segment just for the balance of the year and the cadence and how that evolves throughout the balance of 'twenty three thank you so much.
Go ahead, David maybe I can take that one so when you when you look at the first quarter.
Okay.
Sorry, there we go.
When you look at the first quarter of course, the pricing as we've talked about was influenced also by EMEA and just maybe just chat a little bit about that just to give you some perspective.
As we mentioned Chris in the call that we had fairly significant currency headwinds in EMEA in quarter one.
The price for value and against cost. It was also against the currency headwinds that we faced so thats important as we've indicated.
Our pricing remains on track.
For the full year against our original guide that we made for pricing.
The numbers are.
Significantly consistent whether you look at this the seed business, where we expect high signal digit pricing for the full year.
Crop protection, where we expect low to mid single digit pricing for the full year for crop. So no no change from that and again first quarter very much influenced by that EMEA phenomenon that I mentioned to you.
Thanks very much.
Sort of a two part question.
Is your mix in corn seeds in North America improving.
And making an appreciable difference to your corn economics.
And second in terms of cash flows.
Cash flows year over year.
Or lower by $600 million.
And a big piece of that was accounts payable and that accounts payable sequentially went up and down $950 million.
And normally.
Alright decreased $950 million and normally.
It decreases maybe $400 million.
What's going on with payable for your payables be higher in 2000.
23, then in 'twenty two how does that line work, what's going on there.
Do you want me to maybe take the cash first Tim and then you can come back and talk about CA North America.
So Jeff Good morning, this is Dave.
So you're right the cash flow was $3 5 billion use of cash in the first quarter compared to $2 9 billion.
In Q1 of 2022.
As you know that was really related to you would expect significant related to receivables.
Balances with the growth that we.
Relatively neutral contribution from inventories.
In the quarter on a period over period basis.
The payables is really timing related.
It's a good call out we expect that to normalize over the course of the year, there's a number of factors.
That influenced that we can explain a little more of that detail if it makes sense offline, but just.
To know that number one it's a good callout number two we do expect that to normalize over the course of 2023.
By the way the cash forecast.
That we had for the quarter were basically slightly ahead of our own internal plan. So the numbers that youre looking at are consistent with what our own expectation as was and consistent with what the guidance that we've updated today for cash flow for the year.
Hey, Jeff.
The first question I guess on the mix, if we're seeing an improving mix and in corn technology. What I'd say is when you look over the course of the season.
Technology mix doesn't vary that much on a year to year basis farmers get comfortable with certain types of technology. It is critical for their operation. They can plan accordingly for that and.
And in terms of in terms of the.
Year to year shift you might have a point or two shift, but it tends to be very consistent I think what you are seeing in terms of first quarter versus first half is we had a little bit different mix in terms of the out the door sales and so we probably had a lower representation of of the pioneer and the sales rep model and more dealer or distributor which will.
Primarily <unk>.
The retail as well as in the south and southeast where pioneer.
Is going through distribution as well, so probably saw more of a mix effect on the quarter.
In terms of channel versus technology in and again, our technology, they don't change that much.
I would just emphasize we had kind of a miserable and nevarach in beginning of April . So that's why we ended up with a higher percentage of from a weather standpoint.
From a higher percentage of call it dealer distributor business and to farmers through our agents, so, but but the technology mix doesn't change on a year to year basis. So much.
And our next question will come from Steve Byrne with Bank of America.
Yes. Thank you I would like to better understand what you mean by the.
The shortened saphena season.
Perhaps you can break down that 41% decline in feed volume co Nab has superior corn area.
Honestly up year over year, so I don't quite understand it perhaps it was a pull forward from the fourth quarter.
<unk> how much of it was due to just <unk>.
Insufficient seed supply.
Hey, Steve Good morning, It's Tim I'll take this so there are a couple of things happening in terms of seed in Brazil, and we knew we were going to be tight on supply and as you called out there and we've been talking about that I think for probably the last couple of quarters.
And.
<unk> continued.
And so Mato Grosso, which is about half of Sapremia was planted on a relatively timely basis, but when you get into Sao Paulo, and then as your US in paradigm was a much more delayed and so in the end there were fewer hectares planted and.
You are right <unk> is showing about 3% increase we had planned and expected for it to be more like 10%. So that's where we talk about the season being short shorten and in terms of the timing.
Was fourth quarter, all but bigger it was and part of that was because farmers knew we were going to be tight on supply and they physically wanted to have that seed and so there was a pull from our from our farmer customers to get that seed in their hand, when you look at it on a seasonal basis.
So with the three let's say, let's assume the 3% area increase take our take our volume in the fourth quarter and the first quarter were actually about flat on volume.
And as we go forward so I'll touch on the whole question around <unk>.
Round supply just so we can do it.
The door on that yes, we did take a different approach in terms of <unk>.
Focusing much more on summer production and we're much less dependent upon just in time are suffering a seed production. So just like farmers have a summer season and a supreme your season, we produce over both we increase the mix of <unk>.
Production more towards the summer season, as we sit here today, a significant portion of the seed that we're going to use for the upcoming summer in Sapremia seasons has either been harvested or it's very close to being harvested. So we're in a materially better position to meet the needs of the market base.
Based on the growth trajectory and as we look at next year, we expect that Brazil will continue to increase.
Both soybean area and Sapremia.
Area and that we're going to be in a good position to meet the needs.
And we have a question from Kristen Owen with Oppenheimer.
Great. Thank you so much for taking the question.
I was wondering if you could just talk a little bit about what youre seeing on the ground in terms of the flooding in Iowa.
The impact to our planting season or just how we should think about maybe the puts and takes positives or negatives that may come from that event.
You see it throughout the rest of the year. Thank you.
I think that said my way again Kristen good morning, So in terms of the state of the season I would describe overall, we're off to a decent start with planning progress and were add on corn. We're at about the five year average as of Monday, when the USDA last reported and we are slightly ahead of the five year average on on.
On soybeans and so again, it's it's despite getting off to a really pretty slow start at the beginning of April as we were working through the end of in the end of it.
Winter and really moving towards spring conditions across the corn belt. All indications are that we're going to continue to get the crop in the ground on a timely basis. So we do have some isolated places where we've.
<unk> had some river flooding due to the snow melt and you pointed out the northeast <unk> is one of those areas.
Another area that we're looking really closely at is the northern plains or the Red River Valley.
Tuesday afternoon, I had a conversation with our area leader there to understand where we were sitting in it actually tremendous amount of progress has been made up there and we're very optimistic that.
That farmers are going to be able to get most or nearly all of this crop in the ground. So yes.
The other thing we got to remember is that we have large large pharma customers and they are highly motivated to get the crop in the ground. So.
We've got about 30 days of good corn planting window here call. It the month of.
May in front of us and as the season opens in those areas farmers are going to be able to move fast and.
They are very motivated to get that get that corn in the ground. So we'll continue to watch it but as of right now I would not I would not put up a red flag on that.
And we have a question from Brian .
I just wanted <unk> with RBC.
Okay.
Great. Thanks for taking my question good morning.
Your results look.
Good thought.
<unk> seen from maybe some of your peers.
Was that would you attribute that to maybe share gains.
In crop protection and new product.
Rollouts or how did you kind of consider your performance versus global AG market trends have you seen any changes in.
In AG markets or is it.
It's more internal.
Yes, I can have Robert and Tim talk about where they think they stand from a share perspective, but at the highest level.
We've been on this strategic journey now for a couple of years.
Where we're trying to really drive the portfolio through some choices around which countries we operate in and what our product slates look like and really drive the differentiation of new technology around the world and so we've made a series of decisions I think we've been prudent with our SG&A, Dave referenced that essentially.
Flat for the last couple of years on an apples to apples basis.
And really trying to focus on our controllable.
So and then of course, we do have a very strong lineup from an R&D pipeline perspective, some of those new products now are coming into the marketplace both in seed and.
And in CP, and I think that is allowing us.
To drive.
Market acceptance of these products and allow volume growth. So Robert maybe talk a little bit about what youre seeing and then Tim can do the same thanks Chuck.
On the CPE side, let me start with yes.
We continue to see the market.
We'll grow on a year over year basis, even in 'twenty, three where we're expecting from the non glyphosate take glyphosate out about 6% to 8% or mid single digits really is really the more better normal.
Are the better number.
For growth on total total.
Market. When you began to look then at how we performed.
From a market standpoint, 2022, the organic growth for the for the industry was in the.
The mid teens.
And we grew as you saw in the Q4 report.
About 20% on organic growth. So we expect we picked up a few points of market share around the globe.
Obviously, all the numbers aren't totally and so we got to see how things things settle out, but we do expect that we've gained a little bit over the last year.
Project that forward into this year and what's happening.
The volume is growing from crop protection around the world and for us as well the shift that I talked about earlier is just timing.
And so the demand remains very strong as we see it.
And for US, it's really centered around.
The differentiation and the strategy that we put in place to be differentiated and sustainably advantaged in our portfolio and thats really being driven by two areas, primarily new product growth as you saw in first quarter was up and we expect that we will be up across the year from our new products and <unk> <unk> continue to be a franchise.
It will be over $1 billion. This year and it is continuing to grow. So when you begin to look at how we are different in the market we're continuing to.
Be able to deliver new technologies to the growers, that's really help them add value and yield to their to their farm. So those are some of the things thats driving us how we see the numbers a little bit there across the last year and first quarter.
And our read on the seed side, obviously, it's too early to call 2023 on on a market share standpoint.
We felt good about our order position is that for both corn and soybeans.
In North America and Europe .
As the season is going on so we'll kind of wait and see how the seasons develop but.
But feel.
Pretty decent about where we're sitting right. There in terms of how we performed over the over the past several seasons much like Robert said, we care a lot of momentum in the marketplace right now and.
And on the seed side, we've been growing.
Holding or growing market share.
For the last several seasons.
Many of the largest markets out there so north America, corn and soy last year. We we gained about one point, each which is which is significant we've had multiple years of share growth in Europe on corn and sunflowers and.
And up until this past sapremia season, we've been on a very positive share track.
Across Brazil as well so.
When we think about unit volume as important because it is a metric that's key in the marketplace. We also look at the value share out there as well and I think when you look at the combination of strong unit growth as well as the pricing we've been able to deliver over the past.
Seasons as well, we're also gaining on that value side as well so feel very comfortable about where we're at in and something that we do watch as a key metric for our business.
Okay.
And our next question will come from Joshua Spector with UBS.
Hi, Good morning. This is Lucas Beaumont answer Josh just wanted to clarify the earlier comments on the EBITDA.
So we are implying that the second quarter would be one six to $1 7 billion.
I need to send in the first half.
If that's right can.
Can you guys sort of implied $7 million to $800 million in the second half.
Could you help US bridge today is sort of how you get from the 465 in the second half last year that seven to 800 this year. Please.
Thanks.
Yes. This is Dave I can give you a little bit of additional color on that so.
Sure.
Again, it's against the backdrop of the of the EBITDA Guide as you cited that we've given for the full year call. It 3 billion $6 50.
At the midpoint when you look at the pattern for this year, we would expect revenues to be slightly different but roughly in line with last year, So roughly 60% first half 40% second half.
On the other hand, London and the EBITA as I've said, if you look at last year, we had about.
85% little over 85% of our EBITDA that was generated last year was generated.
In the in the first half we're going to be some 300 to 400 basis points likely less than that in terms of one H 2023, EBITDA as a percent of the total year compared to 2022, so when you do that.
Backend amount, which you get is you still have growth obviously in the second quarter, but it's more muted for the reasons that we talked about the timing of EMEA and the shift out of Latam, mostly from one <unk> last year more significantly one inch last year into a more normalized pattern of one age to age for this year.
So that's really that's really the difference and again that earnings when you look at that distribution, it's not that much different than we've had pre 2022 levels. So hopefully that helps.
Okay.
And we have a.
Question from Dan <unk> with Barclays.
Yes.
Good morning, and thank you very much congrats on the results.
Wanted to follow up just a little bit on the short and medium term impact is to your guidance and some of the strategic announcements you've made so how should how should we think about the portfolio execution on these exits and how is that going to shape is that all baked in into the guidance for this year, one of the main impact and where.
Do you see maybe potential to increase forever.
The.
To get closer to call it to the higher end of the range in the long run versus the lower end of the range, but I like kind of the levers we should consider here. Thank you.
Dave you want to take that one yes, I think one of the things we can say.
So if you will to active ingredients excellent as well.
Some of the geographies that we're exiting so the majority of that is going to be completed over the course of 2023 and that's baked into our guidance now importantly, when you look at the.
The numbers in terms of the significance of those exits it really does have a big impact on the on the on the figures. So for example, when you look at total courts. However for the full year and now I'm talking just specifically.
About about volume when you look at the full year on an adjusted basis.
What we're going to see is positive growth.
Of over 3% for total core Teva, it's really significant when you look at the at the crop protection business.
The significance of exits because when you include both the impact of product exits and also the decision to exit Russia, which as you know we announced in 2022.
I mentioned for the for the first quarter.
Crop protection volume would actually be up and for the full year, it's going to be up attractively mid single digits. When you adjust for those strategic decisions. So I think a couple of takeaways I think number one relative to your question we're absolutely on track it's.
It's built into our numbers youre seeing that as Chuck said in terms of the quality of earnings Youre seeing that in terms of the margin lift that we're generating in the guide that we've given you for the full year and second the optics are fairly significant when you look at the volume numbers when you adjust for those.
The numbers are as we've said are pretty attractive and continue to contribute to our strong organic growth outlook that we've shared with you today.
Thank you and that does conclude the question and answer session. I will now turn the conference back over to Kim Booth for any additional or closing remarks.
Okay. Thank you and that concludes today's call. We thank you for joining and for your interest in core Teva. We hope you hope you have a safe and wonderful day.
Well. Thank you that does conclude today's conference. We do thank you for your participation have an excellent day.